Keros Therapeutics, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Keros Therapeutics, Inc. (KROS) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $0.36 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-08-03
- Keros Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2026-03-31 was $0.48, a 0.00% change year-over-year.
- Keros Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2025-03-31 was $0.48, a 98.31% decline year-over-year.
- Keros Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2024-03-31 was $28.37, a 9.66% increase year-over-year.
- Keros Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2023-03-31 was $25.87, a 523.37% increase year-over-year.
- Keros Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2025 was $2.05, a 93.27% decline from fiscal 2024.
- Keros Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $30.47, a 123.06% increase from fiscal 2023.
- Keros Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $13.66, a 164.22% increase from fiscal 2022.
- Keros Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $5.17, a 256.55% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.36 10-Q · filed 2026-08-03 | |||
| 2026-03-31 | $0.48 10-Q · filed 2026-05-14 | |||
| 2025-12-31 | $2.05 10-K · filed 2026-03-04 | |||
| 2025-09-30 | $0.35 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | $0.34 10-Q · filed 2025-08-06 | |||
| 2025-03-31 | $0.48 10-Q · filed 2025-05-06 | |||
| 2024-12-31 | $30.47 10-K · filed 2025-02-26 | |||
| 2024-09-30 | $29.16 10-Q · filed 2024-11-06 | |||
| 2024-06-30 | $30.02 10-Q · filed 2024-08-07 | |||
| 2024-03-31 | $28.37 10-Q · filed 2024-05-08 | |||
| 2023-12-31 | $13.66 10-K · filed 2024-02-28 | |||
| 2023-09-30 | $16.73 10-Q · filed 2023-11-06 | |||
| 2023-06-30 | $16.66 10-Q · filed 2023-08-07 | |||
| 2023-03-31 | $25.87 10-Q · filed 2023-05-04 | |||
| 2022-12-31 | $5.17 10-K · filed 2023-03-03 | |||
| 2022-09-30 | $4.62 10-Q · filed 2022-11-03 | |||
| 2022-06-30 | $6.25 10-Q · filed 2022-08-04 | |||
| 2022-03-31 | $4.15 10-Q · filed 2022-05-05 | |||
| 2021-12-31 | $1.45 10-K · filed 2022-03-09 | |||
| 2021-09-30 | $0.66 10-Q · filed 2021-11-04 | |||
| 2021-06-30 | $0.73 10-Q · filed 2021-08-05 | |||
| 2021-03-31 | $0.53 10-Q · filed 2021-05-06 | |||
| 2020-12-31 | $0.34 10-K · filed 2021-03-25 | |||
| 2020-09-30 | $0.33 10-Q · filed 2020-11-10 | |||
| 2020-06-30 | $0.32 10-Q · filed 2020-08-13 | |||
| 2020-03-31 | $0.28 10-Q · filed 2020-05-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |